Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glucon Inc.

www.glucon.com

Latest From Glucon Inc.

GlucoLight Makes Non-Invasive Glucose Monitoring Real

When GlucoLight was founded in 2003 to bring to market an optical platform for non-invasive glucose monitoring-specifically, optical coherence tomography-its founders decided to set themselves apart from the pack in two ways. First, they would focus on generating clinical data, and letting that data speak for itself. The company has conducted six clinical trials to date. Second, they would validate its platform in an emerging market that needs a technological solution but that is well-validated from the clinical perspective: glucose monitoring in the hospital critical care environment. This market also offers a faster time to market because there is no requirement to miniaturize the monitor for the ICU environment. Part of a group of articles that includes: "Where are They Now? Checking in on Three Glucose Monitoring Companies," "A Decade of Development of SMSI: Will it Yield Improved Accuracy in CGM?" and "Pelikan Swoops in on the Big Four."
Medical Device

Dealmaking Roundup February 2007

Summary of recent device mergers and acquisitions, alliances, and financings.
Business Strategies

Devices for a Diabetes Epidemic

With an increasing emphasis on tight glycemic control in diabetes care, innovative devices could play a big role, but diabetes is a deceptively complex market. Innovative companies need to differentiate themselves, yet not venture too far outside existing industry dynamics. As the first real-time continuous glucose monitors come to market, a handful of start-ups hopes to be ready for the second generation. Many of these are taking a side excursion into the market for in-hospital glucose monitoring, once a sleepy market but now growing rapidly as outcomes data shows reduced mortality and morbidty in intensively managed hyperglycemic hospital patients.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Glucose Testing
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Glucon Medical Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Glucon Inc.
  • Senior Management
  • Daniel Goldberger, CEO
    Benny Pesach, PhD, VP, R&D
  • Contact Info
  • Glucon Inc.
    Phone: (888) 458-2661
    Boulder, CO
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register